Related Experiment Video

Updated: Jun 12, 2026

Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors
06:07

Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors

Published on: August 5, 2022

More questions than answers about the potential anticancer agents: DNA methylation inhibitors

Xiao-ping Zou1, Bin Zhang, Ying Liu

  • 1Department of Gastroenterology, Drum Tower Hospital Affiliated to Medical School of Nanjing University, Nanjing, Jiangsu 210008, China. zouxiaoping795@hotmail.com

Chinese Medical Journal
|June 10, 2010
PubMed
Abstract

Insights

DNA methylation inhibitors show promise in cancer therapy by reversing tumor suppressor gene expression. However, further research is needed to optimize their effectiveness as targeted anticancer drugs.

Area of Science:

  • Oncology
  • Epigenetics
  • Pharmacology

Background:

  • DNA methylation plays a crucial role in cancer development.
  • Aberrant DNA methylation patterns are hallmarks of various cancers.
  • Targeting epigenetic modifications is a growing area in cancer research.

Purpose of the Study:

  • To review the current status and future perspectives of DNA methylation inhibitors in cancer therapy.
  • To critically assess the emerging role of these agents in clinical practice.

Main Methods:

  • A comprehensive literature search was conducted using PubMed.
  • Relevant English papers published from April 1988 to January 2010 were included.
  • Search terms included "DNA methylation", "demethylation", and "cancer".

Main Results:

  • DNA methylation inhibitors can induce demethylation of tumor suppressor genes, restoring their expression in different tumor types.
  • These agents demonstrate potential as cancer therapeutics.
  • Significant challenges remain in achieving the specificity and efficacy comparable to targeted anticancer drugs.

Conclusions:

  • Further elucidation of precise tumor methylation profiles is essential.
  • Development of novel agents targeting specific genes holds promise for future cancer therapy.
  • Optimizing DNA methylation inhibitors requires a deeper understanding of their mechanisms and clinical applications.

More Related Videos

Enhanced Reduced Representation Bisulfite Sequencing for Assessment of DNA Methylation at Base Pair Resolution13:47

Enhanced Reduced Representation Bisulfite Sequencing for Assessment of DNA Methylation at Base Pair Resolution

Published on: February 24, 2015

Methylated DNA Immunoprecipitation21:24

Methylated DNA Immunoprecipitation

Published on: January 2, 2009

Related Concept Videos

Epigenetic Regulation01:37

Epigenetic Regulation

Epigenetic changes alter the physical structure of the DNA without changing the genetic sequence and often regulate whether genes are turned on or off. This regulation ensures that each cell produces only proteins necessary for its function. For example, proteins that promote bone growth are not produced in muscle cells. Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
X-chromosome...
Epigenetic Regulation01:46

Epigenetic Regulation

Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
Phase II Reactions: Methylation Reactions01:17

Phase II Reactions: Methylation Reactions

Methylation is a phase II biotransformation process involving the attachment of a methyl group to a substrate. Enzymes known as methyltransferases orchestrate this reaction.
The mechanism of methylation unfolds in two stages. The first stage sees a methyltransferase enzyme facilitating the transfer of a methyl group from S-adenosylmethionine (SAM) to the substrate, forming S-adenosylhomocysteine (SAH). The second stage involves further metabolism of SAH into homocysteine, which can be recycled...
Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
Inhibitors of Bacterial DNA Synthesis01:28

Inhibitors of Bacterial DNA Synthesis

Bacterial pathogens depend on precise and efficient DNA replication to sustain infection. Two type II topoisomerases—DNA gyrase and topoisomerase IV—are critical to this process, as they resolve DNA supercoiling and unlink chromosomes during replication. Fluoroquinolones, synthetic derivatives of quinolones, exploit this mechanism by stabilizing the transient DNA–enzyme cleavage complex, preventing strand religation, and causing lethal double-strand breaks. These antibiotics are selectively...
DNA Microarrays02:34

DNA Microarrays

Microarrays are high-throughput and relatively inexpensive assays that can be automated to analyze large quantities of data at a time. They are used in genome-wide studies to compare gene or protein expression under two varied conditions, such as healthy and diseased states. Microarrays consist of glass or silica slides on which probe molecules are covalently attached through surface functionalization. Most commonly, the slides are prepared through the chemisorption of silanes to silica...